Streptococcal pneumonia
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- A febrile disease caused by streptococcus pneumoniae.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Streptococcal pneumonia
- Therapeutic area
- Infectious Disease
- streptococcal pneumonia
- Streptococcus pneumoniae caused pneumonia
- Streptococcus pneumoniae pneumonia
- pneumococcal pneumonia
- pneumonia due to streptococcus
- streptococcal pneumonia
- Severity
- Severe
- Acquired
- Inflammatory
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0005972
- Parent condition
- MONDO:0004652
Related records
Broader conditions (19)
- Bacterial infectious disease
- Bacterial pneumonia
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Gram-positive bacterial infections
- Human disease
- Infectious disease
- Inflammatory disease
- Lower respiratory tract disorder
- Lung disorder
- Pneumococcal infection
- Pneumonia
- Pneumonitis
- Respiratory system disorder
- Respiratory tract infectious disorder
- Streptococcal infection
Trials (52)
- A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
- A Study of Streptococcus Pneumonia Colonisation and Invasive Disease in Cambodian Children
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
- An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 Years
- Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial
- Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
- Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
- Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)
- Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals
- Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4
- Evaluation of PCV Schedules in a Naive Population in Vietnam
- Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4
- Humoral Determinants of Immunity to Pneumococcal Infection
- Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients
- Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults
- Immunogenicity and Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Healthy Volunteers Aged 2 Years and Above
Drugs in development (3)
- Aluminum hydroxide Phase 2
- Linezolid Phase 3
- Sodium chloride Phase 1
Other linked drugs (1)
- Pazufloxacin